drug · antibody
ivonescimab
pre_registrationupdated 3mo agoby $SMMT Summit Therapeutics Inc.🔗 ChEMBL
community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 18 investigational indications.
indications
indications
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying ivonescimab
- phase2Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
- phase2A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)
- phase2Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
- phase2SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer
- phase2Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.
- phase3Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- phase2Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
- phase2A Study of Ivonescimab in People With Leiomyosarcoma
News(10)
- Merck’s Moderna-partnered vaccine success clears view of post-Keytruda futureInvestors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.biospace · 14h ago
- Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, moreAmylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; p…biospace · 1d ago
- Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in ChinaSummit Therapeutics and Akeso’s next-generation cancer drug ivonescimab earned an approval in China last week for first-line patients with certain forms of lung cancer. But it came with an updated…endpoints · 3d ago
- Summit, Akeso’s China approval celebration cut short as survival benefit degradesIvonescimab notched its third approval in China last week, but the label update has tempered expectations for the Summit Therapeutics/Akeso drug, showing that progression-free survival declines ove…biospace · 3d ago
- Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in ChinaWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 8d ago
- Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combinationAfter keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…fiercebiotech · 22d ago
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 24d ago
- Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsSummit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…biospace · 27d ago
- Summit and Akeso sharpen case for ivonescimab with new Western dataSummit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…biospace · 29d ago
- STAT+: Pharma tries to tamp down broad China restrictionsAI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readoutstat · 29d ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that